Cyclophosphamide post-haploidentical stem cell transplantation experience in an infant with IPEX syndrome
Haploidentical transplantation with a post-transplant cyclophosphamide regime can be a viable therapeutic option for patients with IPEX syndrome, lacking an HLA-identical donor, with promising outcomes based on the follow-up data.
Authors
- Harry Pachajoa (ORCID: https://orcid.org/0000-0003-2672-0439)
- Rodrigo Lemus (ORCID: https://orcid.org/0000-0003-2511-6563)
- Diego Medina (ORCID: https://orcid.org/0000-0002-1465-7957)
- Alexis A. Franco (ORCID: https://orcid.org/0000-0002-3173-6059)
- Manuela Olaya (ORCID: https://orcid.org/0000-0002-3239-8928)
- Rafael Milanés (ORCID: https://orcid.org/0000-0002-6693-4442)
- Camila Ariza-Insignares (ORCID: https://orcid.org/0000-0002-6989-7587)
- Ángela Devia (ORCID: https://orcid.org/0000-0003-1845-9082)
- Ángela Restrepo (ORCID: https://orcid.org/0000-0002-3408-0796)
Institutions
- Fundación Valle del Lili (CO)
- Icesi University (CO)
Publication Details
- Journal
- Biomédica
- Published
- 2025-09-22
- DOI
- https://doi.org/10.7705/biomedica.7755
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00